Kazia Therapeutics Limited
Biotechnology, Barangaroo, Connecticut, 06901, United States, 1-10 Employees
Who is KAZIA THERAPEUTICS LIMITED
Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused drug development company. Our lead program is paxalisib, which is being developed to treat glioblastoma (GBM), the most co...
Read More
-
Headquarters: Barangaroo, Connecticut, 06901, United States
-
Date Founded: 1994
-
Employees: 1-10
-
Revenue: Under $1 Million
-
Active Tech Stack: See technologies
-
CEO:
John Friend
Email
Phone
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from KAZIA THERAPEUTICS LIMITED
Kazia Therapeutics Limited Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Kazia Therapeutics Limited
Answer: Kazia Therapeutics Limited's headquarters are located at Barangaroo, Connecticut, 06901, United States
Answer: Kazia Therapeutics Limited's official website is https://kaziatherapeutics.com
Answer: Kazia Therapeutics Limited's revenue is Under $1 Million
Answer: Kazia Therapeutics Limited's SIC: 2834
Answer: Kazia Therapeutics Limited's NAICS: 325412
Answer: Kazia Therapeutics Limited has 1-10 employees
Answer: Kazia Therapeutics Limited is in Biotechnology
Answer: Kazia Therapeutics Limited contact info: Phone number: Website: https://kaziatherapeutics.com
Answer: Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused drug development company. Our lead program is paxalisib, which is being developed to treat glioblastoma (GBM), the most common and aggressive form of primary brain cancer in adults. There are few treatment options for sufferers of GBM and around 65% of sufferers do not respond to currently available treatments. The condition affects around 133,000 people globally per annum and the potential addressable market is worth more than US$1 billion. Kazias drug paxalisib, commenced recruitment to GBM AGILE, a pivotal study in glioblastoma, in January 2021. Eight additional studies are active in various forms of brain cancer. Paxalisib was granted Orphan Drug Designation for glioblastoma by the US FDA in February 2018, and Fast Track Designation for glioblastoma by the US FDA in August 2020. Kazia is also developing EVT801, , a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data for EVT801 has shown it to be active against a broad range of tumour types and has provided compelling evidence of synergy with immuno- oncology agents. A phase I study is expected to begin in CY2021. Competitive Advantages: - Lead program, paxalisib, sourced from the worlds most successful cancer drug developer, Genentech - Experienced team with extensive backgrounds in big pharma and biotech - Around 65% of GBM sufferers do not respond to current treatments - Multiple shots on goal with collaborations progressing in other cancers; largely funded by participating hospitals
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month